The New Plague: False Claims Liability Based on Inequitable Conduct During Patent Prosecution
Posted by Social Science Research Network
The New Plague: False Claims Liability Based on Inequitable Conduct During Patent Prosecution Gregory Michael (University of California), William J Newsom (Cooley LLP) & Matthew Avery (Baker Botts LLP)
Abstract: In January 2009, Amphastar Pharmaceuticals filed a first of its kind qui tam suit on behalf of the federal government and several states alleging that its competitor, Aventis Pharma, violated the Federal False Claims Act (FCA) when it fraudulently acquired a patent and then overcharged the government for its patented drug. By utilizing a fraudulently acquired patent to elevate the price of Lovenox, a drug for treating deep-vein thrombosis, Amphastar alleged that Aventis had overcharged the government for every Lovenox pill purchased with government funds, including all prescriptions funded in part by Medicare or other federal insurance programs. The FCA provides a means for litigants to pursue recovery for fraud perpetrated against the federal government. In its complaint, Amphastar alleged that Aventis obtained its patent by engaging in inequitable conduct during prosecution of its patent application before the United States Patent and Trademark Office. Our analysis of FCA claims based on this novel inequitable-conduct theory concludes that a patentee could be liable for violating the False Claims Act if (1) the government purchased the patented product, (2) the prices of that product were in fact elevated because of the exclusivity provided by the fraudulently obtained patent, and (3) the patentee knew, deliberately ignored, or showed reckless disregard in deciding to submit a claim for payment from the government at this elevated price. If the court in Amphastar finds Aventis liable under this novel theory, the consequences could be far-reaching. Given the nature of modern patent litigation, with inequitable conduct defenses being nearly ubiquitous, such a ruling could expose nearly every patent holder that does business with the federal government to possible liability under the FCA.
This Article discusses the implications of bringing FCA claims based on an inequitable-conduct theory, explores the rationale behind invoking the FCA in this context, and suggests precautions that practitioners can take in such lawsuits. It proposes a variety of reforms to the False Claims Act to check the problems caused by these types of FCA claims. These proposals may become more relevant after the resolution of the Amphastar case if the court validates Amphastar’s novel theory and others follow suit in bringing FCA claims against pharmaceutical patent holders.
Featured News
Geradin Partners Expands Paris Office with Key Hire
Aug 30, 2024 by
CPI
Judge Accuses Google of ‘Clear Abuse’ in Antitrust Case Over Deleted Employee Chats
Aug 29, 2024 by
CPI
Hong Kong Cleaning Company Employee Charged in Historic Antitrust Investigation Case
Aug 29, 2024 by
CPI
Inside the Yelp Suit: Allegations of Google’s Abuse of Search Power
Aug 29, 2024 by
CPI
AI Safety Bill Clears Hurdle in California, Heads to Governor’s Desk
Aug 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 22, 2024 by
CPI
CPI Talks… …With Attorney General Phil Weiser
Aug 22, 2024 by
CPI
The Bipartisan Miracle of State Antitrust Enforcement
Aug 22, 2024 by
Gwendolyn J. Lindsay Cooley
Recent Developments in State Antitrust Enforcement: Agriculture and Food Markets
Aug 22, 2024 by
Elizabeth R. Odette
State Attorneys General: Stewards of Consumer Health and Welfare
Aug 22, 2024 by
Brooke Howlett Lovrovich